Evaluation of the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia in the secondary health care in the Brazilian Unified Health System (SUS)
DOI:
https://doi.org/10.1590/s2175-97902022e20400Keywords:
Pharmaceutical care, Anticholesteremic agents, Quality of health assistanceAbstract
Cardiovascular diseases (CVD) are one of the main causes of mortality in the world. Dyslipidemia treatment can reduce the number of deaths caused by CVD, by decreasing the lipid profile. Evaluate the pharmacotherapeutic follow-up effectiveness in patients with dyslipidemia, regarding clinical and laboratory aspects. A quasi-experimental trial was performed in 12 months. The studied population was included patients with dyslipidemia who received a pharmacotherapeutic follow-up, which was evaluated according to the Pharmacotherapy Workup developed by the Brazilian Ministry of Health. Clinical and laboratory evaluations were performed at the baseline, after a 6 and 12-months period. The statistical analyzes were performed with the normality test of Lilliefors, Cramer Von Misses, and Anderson Darling, later the t-paired test. This study demonstrated that after 6-months of intervention, statistically significant results were verified in the reduction of LDL-cholesterol, total cholesterol, increase in HDL-cholesterol, and reduction in the blood pressure. It was observed that for high-risk patients, the achievement of targets in the lipid profile and HbA1C occurred only after 12-months, because, this population needs more aggressive targets and expressive interventions. Pharmacotherapeutic follow-up in patients with dyslipidemia reduced lipid blood levels and promoted positive clinical and laboratory outcomes.
Downloads
References
American Diabetes Association. Cardiovascular disease and risk management. Diabetes care. 2016;39(Suppl 1):S60-71.
Aquino JA, Baldoni AO, Oliveira CDL, Cardoso CS, Figueiredo RC, Sanches C. Pharmacotherapeutic empowerment and its effectiveness in glycemic control in patients with Diabetes Mellitus. Diabetes Metab Syndr. 2018;13(1):137-142.
Brazilian Society of Cardiology. Update of brazilian guideline on dyslipidemia and prevention of atherosclerosis. Arq Bras de Cardiol. 2017;109(2):14-19.
Brazilian Society of Diabetes. Brazilian diabetes society guidelines 2017-2018. SBD 2017; 1: 33 a 39.212220.
Miot HA. Avaliação da normalidade dos dados em estudos clínicos e experimentais. J Vasc Bras. 2017;16(2):88-91. doi: 10.1590/1677-5449.041117.21.
» https://doi.org/10.1590/1677-5449.041117.21
Cesena FHY, Laurinavicius AG, Valente VA, Conceição RD, Santos RD, Bittencourt MS. Estratificação de risco cardiovascular e elegibilidade para estatina com base na diretriz brasileira vs. Norte-americana para manejo do colesterol. Arq Bras Cardiol. 2017;108(6):508-517.
Ellis SL, Carter BL, Malone DC, Okano GJ, Valuck RJ, Baenette DJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adulst: The IMPROVE study. Pharmacotherapy. 2000;20(12):1508-151614.
Federal Council of Pharmacy. Pharmaceutical services directly aimed at the patient, family and community. Contextualization and conceptual framework. CRF-PR. 2016;1:86-88. Available from: http://www.cff.org.br/ userfiles/Profar_Arcabouco_TELA_FINAL.pdf
» http://www.cff.org.br/ userfiles/Profar_Arcabouco_TELA_FINAL.pdf
Geurts MME, Stewart RE, Brouwers JRBJ, de Graeff PA, de Gier JJ. Implications of a clinical medication review and a pharmaceutical care plano f polypharmacy patients with a cardiovascular disorder. Int J Clin Pharm. 2016;38:808-815. Available from: https://doi.org/10.1007/s11096-016-0281-x.
» https://doi.org/https://doi.org/10.1007/s11096-016-0281-x
Ministry of Health (Brazil). Clinical protocols and therapeutic guideline. Serie A, Standards and technical manuals. 2010;2(1). Available from: portalms.saude.gov.br/protocolos-e-diretrizes
» portalms.saude.gov.br/protocolos-e-diretrizes
Ministry of Health (Brazil). Pharmaceutical care in the primary care. Book 2: Training for implementation of pharmaceutical clinic services. Ministry of health. 2015;1:17-20. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/cuidado_farmaceutico_atencao_basica_saude_2.pdf
» http://bvsms.saude.gov.br/bvs/publicacoes/cuidado_farmaceutico_atencao_basica_saude_2.pdf
Ministry of Health (Brazil). National list of essential medicines-RENAME 2017. Ministry of Health, 2017a;1:16-56. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_rename_2017.pdf
» http://bvsms.saude.gov.br/bvs/publicacoes/relacao_nacional_medicamentos_rename_2017.pdf
Ministry of Health (Brazil). Ordinance nº 1 of September 28, 2017. Consolidation of rights standards and duties of health users, the organization and functioning of the Unified Health System. Official diary of union nº 190 of October 3, 2017b, section 1, page 1. Available from: http://portalarquivos.saude.gov.br/images/pdf/2017/outubro/26/Matriz-Consolida----o-01.pdf
» http://portalarquivos.saude.gov.br/images/pdf/2017/outubro/26/Matriz-Consolida----o-01.pdf
Ministry of Health (Brazil). Pharmaceutical services in primary health care. Book 1, Pharmaceutical Care in Primary Care. Ministry of Health. 2014a;1:53-93. Available from: bvsms.saude.gov.br›bvs›servicos_farmaceuticos_atencao_basica_saude
» bvsms.saude.gov.br›bvs›servicos_farmaceuticos_atencao_basica_saude
Ministry of Health (Brazil). Primary care notebooks. Strategies for the care of people with chronic illness. Ministry of Health. 2014b:1;111-113. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/estrategias_cuidado_pessoa_doenca_cronica_cab35.pdf
» https://bvsms.saude.gov.br/bvs/publicacoes/estrategias_cuidado_pessoa_doenca_cronica_cab35.pdf
Nedel WL, Silveira F. Os diferentes delineamentos de pesquisa e suas particularidades na terapia intensiva. Rev Bras Ter Intensiva. 2016;28(3):256-260. Avaliable from: http://www. scielo.br/pdf/rbti/v28n3/0103-507X-rbti-28-03-0256.pdf
» http://www. scielo.br/pdf/rbti/v28n3/0103-507X-rbti-28-03-0256.pdf
Nelson AJ, Rochelau SK, Nicholls SJ. Managing dyslipidemia in type 2 diabetes. Endocrinol Metab Clin N Am. 2017;17:1-17. Available from: https://doi.org/10.1016/j.ecl.2017.10.004.
» https://doi.org/https://doi.org/10.1016/j.ecl.2017.10.004
Obreli-Neto PR, Guidoni CM, Baldoni AO, Pilger D, Souza JMC, Gaeti-Franco WP, et al. Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm . 2011;33(4):642-649.
R Core Team. R: A language and environment for statistical computing. R Foundantion for Statistical Computing, Vienna. Avaliable in: Avaliable in: https://www.R-project.org Acessed on June 10, 2020).
Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. Committee of Clinical Practice Guideline of Korean Society of Lipid and Atherosclerosis. 2018 Guidelines for the management of dyslipidemia in Korea. Korean J Intern Med. 2019;34(5):1171. doi:10.3904/kjim.2019.188.e1
» https://doi.org/10.3904/kjim.2019.188.e1
Sanchez FJ, Larrea AM, Martín JJ, Mochón LG, López del Amo MP, Martínez FM, et al. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: The conSIGUE program. PharmacoEconomics. 2015;33(6):599-610.
Silva CR, Carvalho BG, Cordoni Júnior L, Nunes EFPA. Dificuldade de acesso a serviços de média complexidade em municípios de pequeno porte: um estudo de caso. Ciência & Saúde Coletiva. 2017;22(4):1109-1120. Available from: <https://doi.org/10.1590/1413-81232017224.27002016>. ISSN 1678-4561.
» https://doi.org/https://doi.org/10.1590/1413-81232017224.27002016
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J. 2000;321:405-412. Available from: https://www.bmj.com/content/bmj/321/7258/405.full.pdf
» https://www.bmj.com/content/bmj/321/7258/405.full.pdf
SUS Computing Departament (DATASUS) [internet]. [Health, epidemiological and morbidity information]. [access in may 1, 2019]. Available from: Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=0205&id=6937
» http://www2.datasus.gov.br/DATASUS/index.php?area=0205&id=6937
World Health Organization [internet]. Scale up prevention of heart attack and stroke. [access in may 1, 2019]. Available in: Available in: https://www.who.int/cardiovascular_diseases/world-heart-day/en/CCBY-NC-SA3.0IGO
» https://www.who.int/cardiovascular_diseases/world-heart-day/en/CCBY-NC-SA3.0IGO
World Health Organization. Tecnical package for cardiovascular disease management in primary health care. Health-lifestyle counseling. World Health Organization. 2018. Available from: http://www.who.int/iris/handle/10665/260422
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
